Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?



Status:Completed
Conditions:Smoking Cessation
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - 60
Updated:2/22/2018
Start Date:February 2013
End Date:November 2016

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
The purpose of this study is to examine whether doxazosin will attenuate the ability of
stress to precipitate smoking lapse behavior in treatment seeking daily smokers. Participants
will participate in a smoking cessation attempt after the laboratory sessions.


Inclusion Criteria:

- Ages 18-60

- Able to read and write English

- Smoker

- Motivated to Quit Smoking

Exclusion Criteria:

- Any significant current medical conditions that would contraindicate smoking

- Current Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) abuse or
dependence of other substances, other than nicotine dependence or alcohol abuse

- Positive test results at intake appointment on urine drug screens for illicit drugs

- Past 30 day use of psychoactive drugs including anxiolytics and antidepressants

- Women who are pregnant or nursing

- Suicidal, homicidal or evidence of current severe mental illness such as
schizophrenia, bipolar disorder or major depression, or anxiety disorders

- Participants who have donated blood within the past 6 weeks

- Individuals who are currently taking other medications prescribed for smoking
cessation

- Specific exclusions for administration of doxazosin or any alpha blocker
We found this trial at
1
site
Yale Center for Clinical Investigations, Yale University
New Haven, Connecticut 06519
?
mi
from
New Haven, CT
Click here to add this to my saved trials